WO1999053950A3 - Live vaccines and methods of treatment therewith - Google Patents

Live vaccines and methods of treatment therewith Download PDF

Info

Publication number
WO1999053950A3
WO1999053950A3 PCT/US1999/008530 US9908530W WO9953950A3 WO 1999053950 A3 WO1999053950 A3 WO 1999053950A3 US 9908530 W US9908530 W US 9908530W WO 9953950 A3 WO9953950 A3 WO 9953950A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
live
vaccines
administering
methods
Prior art date
Application number
PCT/US1999/008530
Other languages
French (fr)
Other versions
WO1999053950A9 (en
WO1999053950A2 (en
Inventor
Rebecca M Poston
Paul A Johnston
Vivian W Doelling
Brian D Johnson
Original Assignee
Embrex Inc
Rebecca M Poston
Paul A Johnston
Vivian W Doelling
Brian D Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embrex Inc, Rebecca M Poston, Paul A Johnston, Vivian W Doelling, Brian D Johnson filed Critical Embrex Inc
Priority to EP99917611A priority Critical patent/EP1071453A2/en
Priority to AU35690/99A priority patent/AU3569099A/en
Publication of WO1999053950A2 publication Critical patent/WO1999053950A2/en
Publication of WO1999053950A3 publication Critical patent/WO1999053950A3/en
Publication of WO1999053950A9 publication Critical patent/WO1999053950A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18171—Demonstrated in vivo effect

Abstract

Disclosed herein are methods and pharmaceutical formulations for administering vaccines to birds. In preferred embodiments, the invention provides methods of administering live pathogenic virus vaccines to birds in ovo, more preferably, during the last quarter of in ovo incubation. Interferon, more preferably, Type I interferon, may be advantageously administered in conjunction with live virus vaccines to decrease the pathogenicity thereof. Interferon must be provided at doses sufficient to protect against pathogenicity of the live vaccine, but not at doses so high as to prevent the host from mounting an active immune response. Further provided are pharmaceutical formulations comprising effective doses of live vaccine and interferon. Finally, the present invention provides methods of administering interferon together with live vaccines to young avians to effectively overcome the interfering effects of maternal antibodies.
PCT/US1999/008530 1998-04-17 1999-04-16 Live vaccines and methods of treatment therewith WO1999053950A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP99917611A EP1071453A2 (en) 1998-04-17 1999-04-16 Live vaccines and methods of treatment therewith
AU35690/99A AU3569099A (en) 1998-04-17 1999-04-16 Live vaccines and methods of treatment therewith

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8219698P 1998-04-17 1998-04-17
US60/082,196 1998-04-17

Publications (3)

Publication Number Publication Date
WO1999053950A2 WO1999053950A2 (en) 1999-10-28
WO1999053950A3 true WO1999053950A3 (en) 2000-01-13
WO1999053950A9 WO1999053950A9 (en) 2000-07-13

Family

ID=22169653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/008530 WO1999053950A2 (en) 1998-04-17 1999-04-16 Live vaccines and methods of treatment therewith

Country Status (4)

Country Link
US (1) US6506385B1 (en)
EP (1) EP1071453A2 (en)
AU (1) AU3569099A (en)
WO (1) WO1999053950A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046500A1 (en) 2000-02-29 2001-11-29 Berend Jongsma In ovo protection against infectious bronchitis
IL151039A0 (en) * 2000-02-29 2003-04-10 Wyeth Corp In ovo protection against infectious bronchitis
AR031405A1 (en) 2000-11-21 2003-09-24 Wyeth Corp METHODS AND VACCINES TO CONFERENCE PROTECTION IN OVO AGAINST TURKEY'S RHINOTRACHISIS
AU2003238767A1 (en) * 2002-05-31 2003-12-19 Penn State Research Foundation Dot-elisa for the detection of animal viruses
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
US7438019B2 (en) * 2004-11-29 2008-10-21 Compact Automation Products, Llc Integrated pneumatic actuator and pump for dispensing controlled amounts of a fluid
AU2006279612B2 (en) 2005-08-15 2013-03-21 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines
KR101149687B1 (en) 2006-03-30 2012-05-25 엠브렉스, 인코포레이티드 Methods and compositions for vaccination of poultry
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
US10196616B2 (en) * 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
CN107299155B (en) * 2017-08-18 2020-05-22 福建省农业科学院畜牧兽医研究所 Primer and probe for real-time fluorescence quantitative PCR detection of goose astrovirus
CN109762062B (en) * 2018-09-19 2022-02-25 天津瑞普生物技术股份有限公司 Preparation method of goose gout egg yolk antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004076A1 (en) * 1985-12-30 1987-07-16 The Texas A & M University System Low dosage of interferon to enhance vaccine efficiency
EP0609739A1 (en) * 1993-02-02 1994-08-10 American Cyanamid Company Method of reversing immunosuppression in vaccines
US5397568A (en) * 1989-10-02 1995-03-14 Whitfill; Craig E. Method of treating infectious bursal disease virus infections
WO1998037216A1 (en) * 1997-02-21 1998-08-27 Syntro Corporation Recombinant chimeric viruses and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053583A (en) 1976-03-01 1977-10-11 Smithkline Corporation Live newcastle disease virus vaccines
US5378457A (en) 1981-12-24 1995-01-03 Virogenetics Corporation Interferon sensitive recombinant poxvirus vaccine
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US4689224A (en) 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
JPH04506662A (en) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー Cytokinin and hormone carriers for conjugate vaccines
US5562910A (en) 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
JP3399943B2 (en) 1991-05-06 2003-04-28 アメリカ合衆国 Recombinant virus expressing carcinoembryonic antigen and method of use
AUPN154295A0 (en) 1995-03-06 1995-03-30 Commonwealth Scientific And Industrial Research Organisation Nucleic acid molecule encoding a protein with avian gamma-interferon activity
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5885567A (en) 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004076A1 (en) * 1985-12-30 1987-07-16 The Texas A & M University System Low dosage of interferon to enhance vaccine efficiency
US5397568A (en) * 1989-10-02 1995-03-14 Whitfill; Craig E. Method of treating infectious bursal disease virus infections
EP0609739A1 (en) * 1993-02-02 1994-08-10 American Cyanamid Company Method of reversing immunosuppression in vaccines
WO1998037216A1 (en) * 1997-02-21 1998-08-27 Syntro Corporation Recombinant chimeric viruses and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOWENTHAL J W ET AL: "Coadministration of IFN -gamma enhances antibody responses in chickens.", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 18, no. 8, August 1998 (1998-08-01), pages 617 - 22, XP002122472 *

Also Published As

Publication number Publication date
WO1999053950A9 (en) 2000-07-13
WO1999053950A2 (en) 1999-10-28
EP1071453A2 (en) 2001-01-31
AU3569099A (en) 1999-11-08
US6506385B1 (en) 2003-01-14

Similar Documents

Publication Publication Date Title
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
CA2339089A1 (en) Cold-adapted equine influenza viruses
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
HUP0401606A2 (en) West nile vaccine
WO2005049074A3 (en) Methods for modulating the th2 immuneresponse to an antigen by adding or removing activated carbonyl groups from the antigen
GB9306731D0 (en) Vaccines
JP2003513935A5 (en)
CA2115927A1 (en) Peptides for inducing cytotoxic t-lymphocyte responses to hepatitis b virus
WO2001034189A3 (en) Vaccines for mycoplasma bovis and methods of use
PT1015595E (en) DERIVATIVE PEPTIDES OF LIGACAO (G) PROTEIN FROM RESPIRATORY SYNCYCIAL VIRUS
MXPA02005506A (en) Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens.
AU2005244826B2 (en) Treatment or prevention of respiratory viral infections with immunomodulator compounds
CA2463090A1 (en) Recombinant rabies vaccine and methods of preparation and use
US8105613B2 (en) Vaccine formulation
FI932759A (en) ADJUSTMENT OF IL-4 FOR OVERNING AV PAO VACCINERS IMMUNOGENER VERKANDE IMMUNREAKTIONER
WO2001064244A3 (en) In ovo protection against infectious bronchitis
WO2007135420A3 (en) Defective interfering virus
UA95299C2 (en) Prophylactic or therapeutic agent for viral disease caused by hepatitis c virus
WO2004030614A3 (en) Vaccines containing viruses involved in avian malabsorption syndrome and methods of administration therefor
WO2004100640A3 (en) Marek’s disease virus vaccine
US6383741B2 (en) Method for treatment of canine distemper
IL122829A (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-36, DESCRIPTION, REPLACED BY NEW PAGES 1-36; PAGES 37-44, CLAIMS, REPLACED BY NEW PAGES 37-44; PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999917611

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917611

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999917611

Country of ref document: EP